At the 2020 World Conference on Lung Cancer (WCLC) were presented preliminary results of the patients with relapsed/refractory HER2-overexpressing (IHC 3+ or 2+) NSCLC enrolled in the cohort 1 of the same study (43). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.